Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities. Ikeda J, Shiba N, Kato S, Kunimoto H, et al. Int J Hematol 2025;121:694-705.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ikeda J, Shiba N, Kato S, Kunimoto H, et al. Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities. Int J Hematol 2025;121:694-705.
PMID: 39891826